Valneva Scotland Receives Prestigious Award for Health and Safety Excellence

Livingston (Scotland), August 8, 2024 – Scotland's largest vaccine producer, Valneva Scotland Ltd, based in Livingston, has achieved an esteemed Silver Award for health and safety from the Royal Society for the Prevention of Accidents (RoSPA). These international awards recognise the highest standards of safety and excellence within the workplace, assessing health and safety performance, policies and procedures.

The internationally renowned RoSPA Health and Safety Awards receive almost 2,000 entries annually from over 50 countries, reflecting the largest and most impactful health and safety awards running for 68 years. Silver Award winners demonstrate a high level of performance, supported by robust management systems that consistently drive improvement. This accolade is a reflection of Valneva Scotland's commitment to excellence, setting a benchmark for prestige and inspiring admiration across sectors.

Greig Rooney, Managing Director at Valneva Scotland Ltd said: "Valneva is contributing to a world in which no one suffers from vaccine-preventable diseases. Livingston is the proud home of Valneva’s Centre of Excellence for Manufacturing, producing millions of doses of vaccines every year. This health and safety recognition reflects our commitment to be the best life science organisation to work for, putting our 180-highly skilled team members at the centre of everything we do. I want to thank our Health and Safety team for their diligence and dedication every day.”

Valneva colleagues Paulina Meducka and Kathleen Haddow accepted the prestigious 2024 RoSPA Silver Award during a ceremony held in London, assessing performance throughout 2023.

Kathleen Haddow, OHSE Manager, said: “This momentous award from RoSPA brings international recognition for our safety performance, with an in-depth application process that took nearly three months to complete. Safety is an ongoing priority and baked into our culture at Valneva Scotland, with rigorous standards and ongoing development for our team members.” 

This latest award follows previous recognition for Valneva Scotland in the 2024 Life Sciences Scotland Awards, with double wins in two categories: Innovation - Pharma Services & Drug Discovery and Outstanding Skills Development Award.

For more information about Valneva and its commitment to health and safety excellence, please visit: www.valneva.com.

ENDS

Issued by Perceptive Communicators on behalf of Valneva.

For media enquiries contact:

Hayley Crockett | hayley.crockett@perceptivecommunicators.co.uk | 07713 836 354

Notes to editors

About Valneva Scotland

Advancing vaccines for better lives

Valneva is Scotland’s largest vaccine producer and the second largest in the UK.

Livingston is a manufacturing centre of excellence for Valneva, with around 170-highly skilled manufacturing and scientific staff making two of three licensed vaccines.

Valneva’s state-of-the-art Almeida facility in Livingston, fully opening in 2024, will be amongst the highest specification lab spaces in UK and Europe - one of only six facilities in Europe with Containment Level 3 (CL3) manufacturing capabilities. This facility allows Valneva to work with higher risk biological agents and hazards.

Valneva Scotland aims to be the best life sciences company to work for in Scotland by 2027, with a strong focus on people, development and growth.

Valneva’s Livingston facility is a global leader in sustainable working, with 100% renewable energy and ‘Zero Waste to Landfill’ status.

About Valneva SE

We are a specialty vaccine company that develops, manufactures, and commercialises prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialised and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.

We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines as well as certain third-party vaccines leveraging our established commercial infrastructure.

Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats.